Head And Neck Squamous Cell Carcinoma

The combination of an investigational cell therapy using tumor-infiltrating lymphocytes and pembrolizumab induced responses among a small cohort of patients with metastatic head and neck squamous cell carcinoma, study results showed.

The combination of an investigational cell therapy using tumor-infiltrating lymphocytes and pembrolizumab induced responses among a small cohort of patients with metastatic head and neck squamous cell carcinoma, study results showed.

Immunotherapy did not appear to worsen complications among patients with cancer and COVID-19, according to results of a study presented at American Association for Cancer Research Virtual Meeting: COVID-19 and Cancer.

Weekly cisplatin appeared noninferior to an every-3-weeks dose as part of chemoradiotherapy regimen for certain patients with head and neck squamous cell carcinoma, according to study results presented during the ASCO20 Virtual Scientific Program.

The FDA granted fast track designation to several therapies in development for hematology or oncology indications.

The FDA approved an additional recommended dosage of pembrolizumab, authorizing its use at 400 mg every 6 weeks.

The FDA granted breakthrough therapy designation to three agents in development for oncology indications.

A randomized phase 3 study designed to evaluate the addition of avelumab to chemoradiotherapy for patients with untreated locally advanced head and neck squamous cell carcinoma has been terminated based on the recommendation of the independent data monitoring committee.

The FDA granted breakthrough therapy designation to Debio 1143 for first-line treatment of head and neck cancer, according to the agent’s manufacturer.

The FDA granted fast track designation to ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma and second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma, according to a press release from the drug’s manufacturer.